Tristel PLC · LSE:TSTL
Tristel — Investor Presentation (July 2020)
5 slides from Tristel's investor presentation, Jul 22, 2020
Slide 1: Sales History – Since IPO
SALES HISTORY – SINCE IPO £35,000,000 2019-20 in summary £30,000,000 • 15 years as a public company £25,000,000 • Acquisition of Tristel Italia £20,000,000 • Launch of Cache surface portfolio £15,000,000 • Impact of Covid-19 £10,000,000 • 21% y-o-y sales growth in 2020 £5,000,000 • 17% CAGR since IP
Slide 2: Sales History – By Geography
SALES HISTORY – BY GEOGRAPHY 2019-20 in summary £35,000,000 • UK sales growth 7% £30,000,000 • International sales growth 32% £25,000,000 • International sales benefit from £20,000,000 Tristel Italia contribution – acquired July 19 £15,000,000 • International sales now represent £10,000,000 60% of a
Slide 3: Sales History – By Product Category
SALES HISTORY – BY PRODUCT CATEGORY £35,000,000 2019-20 in summary £30,000,000 • 12% Tristel medical device sales growth £25,000,000 • 139% Cache surface sales growth £20,000,000 Estimated Covid-19 impact £15,000,000 • £500k reduction in Tristel medical £10,000,000 device sales £5,000,000 • £2m incr
Slide 4: Second Half Sales – Covid Impact
SECOND HALF SALES – COVID IMPACT Second half 2019-20 • March: Hospitals build their stock of £3,000,000 all infection prevention products. £2,500,000 • April: Out-patient departments close to all but Covid-19 patients. £2,000,000 Reduced Tristel sales, but Cache sales hit an all time high. £1,500,00
Slide 5: Covid Impact - Production
COVID IMPACT - PRODUCTION Bulk Solution Manufacture 2019-20 February & March 2020 • Senior management team 250,000L prepares a Covid-19 response plan 200,000L April & May 2020 • 100% increase in bulk solution 150,000L manufacture 100,000L • 100% increase in out-sourced sachet filling output 50,000L